Details on the US Food and Drug Administration’s (FDA) plans for launching a pilot project on model-informed drug development (MIDD) began trickling out on Monday with a Federal Register notice.
The International Council for Harmonisation (ICH) released a widely anticipated timetable detailing its plans to issue general guidance on model-informed drug development (MIDD) approaches in drug ...
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of ...
Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances ...
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of ...
RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief ...
Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled modelling in drug development. The partnerships aim to apply AI within ...
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. as President ...
Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon ...
This analysis is by Bloomberg Intelligence Industry Analyst Andrew Galler and Senior Associate Analyst Jack Maltby. It appeared first on the Bloomberg Terminal. Life sciences is among the most ...